Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIORELLA: Fitness- and comorbidity-tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma
2016-003116-12Phase 2Terminated
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Feb 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL) comparing Lenalidomide maintenance with Procarbazine maintenance (2 arms). Primary endpoint: 2-year progression-free survival rate. Started Feb 2019; status: terminated.
02
Drugs
lenalidomideprocarbazine
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2016-003116-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003116-12.